Hospitalized Children, Mycoplasma Infections
Conditions
Brief summary
This study was set up because of an unusual increase in the number of cases of mycoplasma infections in France between June and November 2023. Clinical data from children with mycoplasma infections will be collected to characterise this infection and facilitate hospital management.
Detailed description
In this study, the number of cases will be collected. In addition, we will determine the clinical, biological and microbiological characteristics of these cases. These following data will be collected: signs or symptoms associated with this infection, clinical complications, biological and microbiological tests done during hospitalisation, treatment used during hospitalization, results of thoracic x-ray and lung ultrasound.
Interventions
None listed
Sponsors
Association Clinique Thérapeutique Infantile du val de Marne
Groupe de Pathologies Infectieuses Pédiatriques (GPIP)
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Days to 17 Years
Inclusion criteria
* Age \<18 years (only hospitalized children) * Documented mycoplasma infection (positive multiplex PCR and/or positive serology)
Exclusion criteria
* Refusal by one of the parents or by Child in understanding age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients hospitalized for mycoplasma infections | 1 year | Proportion of hospitalized children due to mycoplasma infections |
| medical characterisation of mycoplasma infections | 1 year | Assessment of clinical, biological and microbiological characteristics of mycoplasma infections cases. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identify risk factors of serious infection | 1 year | Describe what is responsible of serious infection. |
| Identify predictive signs of serious infection | 1 year | what are the warning signs of a serious infection? |
| Type of complications | 1 year | Describe any complications due to infection |
| Patients outcome | 1 year | Proportion of patients recovered |
| healthcare used for infected children | 1 year | Describe healthcare provided during hospitalisation of infected children in order to manage this type of infection |
| treatment used during hospitalisation | 1 year | type of treatment used during hospitalisation to manage the infection |
| clinical description of infected children | 1 year | clinical description of all cases of mycoplasma infections reported during the study |
| Type of mycoplasma involved in infected children | 1 year | characterisation of mycoplasma involved in infection (strain, molecular epidemiology and antibiotic resistance) |
| Assessment of Complementary Diagnostic Test Performance in Lung Disorders | 1 year | To evaluate the performance of complementary diagnostic tests in children with lung disorders, including sensitivity, specificity, and agreement with standard diagnostic methods. |
| Correlation between diagnostic test results in Infected Children | 1 year | To evaluate the relationship between the results of various diagnostic tests in children with infection, aiming to identify patterns or predictors of disease severity. |
Countries
France
Contacts
STUDY_DIRECTORCorinne Levy
Association Clinique Thérapeutique Infantile du val de Marne
PRINCIPAL_INVESTIGATORAnais Chosidow
Hôpital Intercommunal de Villeneuve-Saint-Georges
PRINCIPAL_INVESTIGATOREmilie Pauquet
Hôpital des Enfants, CHU de Bordeaux
Outcome results
None listed